# Ambros Therapeutics funding rounds and investors

As of 14 Oct 2026, Ambros Therapeutics has raised $125M across 1 verified round on record; latest: $125 million Series A led by Enavate Sciences and RA Capital Management, announced 16 Dec 2025.

Innovative medicines for diseases with high unmet medical need, specifically targeting Complex Regional Pain Syndrome Type 1.

Website: https://ambrostherapeutics.com  
Headquarters: Irvine, California  
Page: https://fireround.dev/companies/ambrostherapeutics.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-12-16 | Series A | $125 million | Enavate Sciences, RA Capital Management | Abiogen Pharma, Adage Capital Management, Arkin Bio, Balyasny Asset Management, Janus Henderson Investors, Transhuman Capital | [prnewswire.com](https://www.prnewswire.com/news-releases/ambros-therapeutics-launches-with-125-million-series-a-financing-to-advance-neridronate-through-phase-3-registrational-program-for-complex-regional-pain-syndrome-type-1-302642798.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.